- Received FDA Type 2b feedback providing greater clarity on AEON's integrated biosimilar development strategy combining comparative analytical assessment, human pharmacodynamic studies, and a substantial body of existing comparative clinical evidence -
- Submitted IND for comparative CMAP pharmacodynamic study, with initiation planned for Q1 2027 -
- Expanded analytical evidence supporting molecular similarity to BOTOX®, including approximately 98% coverage of core 150 kDa neurotoxin sequence with 100% identity across all analyzed regions -
- Approximately $6.2 million in milestone warrant proceeds provide additional capital for ongoing ABP-450 development -
ALISO VIEJO, Calif., Nov. 16, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 as a full-label therapeutic biosimilar to BOTOX® (onabotulinumtoxinA), today reported its financial results for the third quarter ended September 30, 2026, and provided a corporate update.
“Over the past several months, we have made important progress in advancing the scientific and regulatory foundation for ABP-450’s development as a biosimilar to BOTOX®,” commented Rob Bancroft, President and Chief Executive Officer of AEON. “Our FDA Type 2b meeting provided valuable direction on integrating comparative analytical and human pharmacodynamic data with an extensive body of existing comparative clinical evidence, while our expanding analytical results continue to strengthen the foundation of our biosimilarity program. Together, these efforts are helping to advance a rigorous, scientifically informed approach to demonstrating biosimilarity to BOTOX®.”
“With our CMAP IND submitted and additional capital secured through the recent milestone warrant exercises, we are positioned to advance the Next phase of development, including the planned initiation of our comparative pharmacodynamic study in the first quarter of 2027. We remain focused on building the evidence necessary to bring a biosimilar to BOTOX® to the U.S. therapeutic market, representing an opportunity of approximately $3.5 billion annually.”
Third Quarter 2026 Highlights and Recent Developments
Liquidity and Capital Resources
The Company reported cash and cash equivalents of $11.4 million as of September 30, 2026, which does not include approximately $6.2 million of proceeds from the exercise of milestone warrants received in the fourth quarter of 2026. The Company expects its cash and cash equivalents as of September 30, 2026, together with these warrant proceeds, to fund operations into the second quarter of 2027, supporting continued execution of the comparative analytical program, preparations for and planned initiation of the CMAP pharmacodynamic study, and ongoing regulatory activities.
Planned ABP-450 Development Milestones
About the U.S. Biosimilar Pathway
The 351(k) biosimilar pathway is grounded in a totality-of-the-evidence approach. The FDA evaluates a proposed biosimilar using the most sensitive and scientifically informative methods available to identify potential differences from its reference product, with comparative analytical assessment providing the scientific foundation. The nature and extent of any additional studies the FDA may require prior to approval are informed by the residual uncertainty remaining after that assessment. Once biosimilarity is established, the FDA has the authority to approve a biosimilar for additional indications of the reference product through scientifically justified extrapolation, without requiring separate clinical studies in each indication.
In October 2025, the FDA issued draft guidance proposing that a comparative efficacy study — a comparative clinical study with efficacy endpoints — may not be necessary where, among other things, a comparative analytical assessment demonstrates that a proposed product is highly similar to its reference product. The draft guidance reflects the FDA’s view that comparative analytical methods are generally more sensitive than comparative efficacy studies for detecting differences between products.
About AEON Biopharma
AEON Biopharma is a biopharmaceutical company pursuing full-label access to the U.S. therapeutic neurotoxin market via biosimilarity to BOTOX®. The U.S. therapeutic neurotoxin market is estimated to be approximately $3.5 billion annually, representing a major opportunity for biosimilar entry. ABP-450 is the same botulinum toxin complex currently approved and marketed for cosmetic indications by Evolus, Inc. under the Name JeuveauÒ. ABP-450 is manufactured by Daewoong Pharmaceutical in a facility that has been authorized by the U.S. Food and Drug Administration, Health Canada, and the European Medicines Agency for the manufacture of third-party botulinum toxin products. AEON has exclusive development and commercialization rights for therapeutic indications of ABP-450 in the United States, Canada, the European Union, the United Kingdom, and certain other international territories. To learn more about AEON, visit www.aeonbiopharma.com.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation statements regarding the Company’s product development and business prospects, and can be identified by the use of words such as “may,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,” “continue” or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. Forward-looking statements in this press release include statements regarding the Company's anticipated cash runway and future capital requirements; the expected proceeds from warrant exercises; the timing, design, initiation and execution of the Company's planned clinical and analytical studies; the sensitivity and potential evidentiary value of the CMAP pharmacodynamic study; the Company's ability to complete the comparative analytical assessment and scientific bridging activities; the potential for the Company's integrated evidence package to support a determination of biosimilarity without a standalone comparative clinical efficacy study; the scope and timing of any future FDA review, approval or indication extrapolation; the Company's regulatory strategy and development plans for ABP-450; the potential market opportunity for ABP-450; and the anticipated contributions of its management Team . These forward-looking statements are based on information currently available to the Company and its current plans or expectations and are subject to a number of risks and uncertainties that could significantly affect current plans. Should one or more of these risks or uncertainties materialize, or the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended, or planned. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee future results, performance, or achievements. Except as required by applicable law, including the securities laws of the United States, the Company does not intend to update any of the forward-looking statements to conform these statements to actual results.
Factors that may cause actual results to differ materially from current expectations include, but are not limited to: (i) the Company’s ability to meet continued stock exchange listing standards; (ii) the Company’s ability to obtain additional and sufficient financing; (iii) the Company’s anticipated financial performance, including cash and cash equivalents; (iv) the Company’s plans regarding any interactions with the FDA; (v) the outcome of any regulatory interactions; (vi) the possibility that the FDA may require additional analytical, pharmacodynamic, clinical or other studies; (vii) the Company's ability to obtain necessary regulatory and institutional approvals, activate clinical sites and initiate its planned studies within anticipated timelines; and (viii) other risks and uncertainties set forth in the sections entitled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in the Company’s filings with the Securities and Exchange Commission (the “SEC”), which are available on the SEC’s website at www.sec.gov.
Contacts
Investor Contact:
Hershel Berry
Blueprint Life Science Group
hberry@Bplifescience.com
Source: AEON Biopharma
| AEON BIOPHARMA, INC. | |||||||
| CONDENSED CONSOLIDATED BALANCE SHEETS | |||||||
| (in thousands, except share data and par value amounts) | |||||||
| September 30, | December 31, | ||||||
|
2026 |
2025 |
||||||
| ASSETS | |||||||
| Current assets: | |||||||
| Cash and cash equivalents | $ | 11,417 | $ | 3,006 | |||
| Prepaid expenses and other current assets | 1,146 | 392 | |||||
| Total Fina Elf current assets | 12,563 | 3,398 | |||||
| Property and equipment, net | 58 | 162 | |||||
| Operating lease right-of-use asset | 798 | 1,052 | |||||
| Other assets | 710 | 948 | |||||
| Total Fina Elf assets | $ | 14,129 | $ | 5,560 | |||
| LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT) | |||||||
| Current liabilities: | |||||||
| Accounts payable | $ | 981 | $ | 942 | |||
| Accrued clinical trials expenses | 929 | 1,426 | |||||
| Accrued compensation | 981 | 2,872 | |||||
| Other accrued expenses | 1,681 | 1,657 | |||||
| Total Fina Elf current liabilities | 4,572 | 6,897 | |||||
| Convertible notes at fair value, including related party amount of $1,969 and $34,600 at September 30, 2026 and December 31, 2025, respectively | 1,969 | 34,600 | |||||
| Operating lease liability | 821 | 893 | |||||
| Derivative liability | — | 14,879 | |||||
| Warrant liabilities | 4,353 | 3,276 | |||||
| Contingent consideration liability | 6 | 42 | |||||
| Other liabilities | 22 | — | |||||
| Total Fina Elf liabilities | 11,743 | 60,587 | |||||
| Commitments and contingencies | |||||||
| Stockholders’ equity (deficit): | |||||||
| Class A common stock, $0.0001 par value; 1,040,000,000 shares authorized at September 30, 2026 and December 31, 2025, and 59,084,675 and 12,105,902 shares issued and outstanding at September 30, 2026 and December 31, 2025, respectively | 14 | 9 | |||||
| Additional paid-in capital | 483,674 | 415,783 | |||||
| Accumulated deficit | (481,302 | ) | (470,819 | ) | |||
| Total Fina Elf stockholders' equity (deficit) | 2,386 | (55,027 | ) | ||||
| Total Fina Elf liabilities and stockholders' equity (deficit) | $ | 14,129 | $ | 5,560 | |||
| AEON BIOPHARMA, INC. | |||||||||||||||
| CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) | |||||||||||||||
| (in thousands, except share and per share data) | |||||||||||||||
| Three Months Ended | Nine Months Ended | ||||||||||||||
| September 30, | September 30, | ||||||||||||||
|
2026 |
2025 |
2026 |
2025 |
||||||||||||
| Operating expenses: | |||||||||||||||
| Selling, general and administrative | $ | 2,990 | $ | 1,933 | $ | 9,884 | $ | 8,316 | |||||||
| Research and development | 1,515 | 597 | 6,488 | 2,485 | |||||||||||
| Change in fair value of contingent consideration | (22 | ) | (37 | ) | (36 | ) | (3,509 | ) | |||||||
| Total Fina Elf operating costs and expenses | 4,483 | 2,493 | 16,336 | 7,292 | |||||||||||
| Loss from operations | (4,483 | ) | (2,493 | ) | (16,336 | ) | (7,292 | ) | |||||||
| Other (loss) income: | |||||||||||||||
| Change in fair value of convertible notes | (214 | ) | (1,877 | ) | (9,154 | ) | (5,362 | ) | |||||||
| Change in fair value of warrants | 7,014 | (236 | ) | 16,611 | 85,950 | ||||||||||
| Loss on issuance of warrants | — | — | — | (75,644 | ) | ||||||||||
| Loss on extinguishment of debt | — | — | (76 | ) | — | ||||||||||
| Loss on derivative liability | — | — | (1,743 | ) | — | ||||||||||
| Other income, net | 148 | 68 | 215 | 263 | |||||||||||
| Total Fina Elf other income (loss), net | 6,948 | (2,045 | ) | 5,853 | 5,207 | ||||||||||
| Income (loss) before taxes | 2,465 | (4,538 | ) | (10,483 | ) | (2,085 | ) | ||||||||
| Income taxes | — | — | — | — | |||||||||||
| Net income (loss) | $ | 2,465 | $ | (4,538 | ) | $ | (10,483 | ) | $ | (2,085 | ) | ||||
| Basic and diluted net income (loss) per share attributable to common stockholders | $ | 0.01 | $ | (0.39 | ) | $ | (0.17 | ) | $ | (0.23 | ) | ||||
| Weighted average shares of common stock outstanding used to compute basic and diluted net income (loss) per share | 89,957,587 | 11,634,946 | 60,548,285 | 8,931,566 | |||||||||||